NEW YORK, July 11, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sarepta investors who were adversely affected by alleged securities fraud between June 22, 2023 and June 24, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/sarepta-lawsuit-submi ...

NEW YORK, July 11, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sarepta investors who were adversely affected by alleged securities fraud between June 22, 2023 and June 24, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/sarepta-lawsuit-submission- ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Sarepta Therapeutics, Inc. during the specified class period of the upcoming lead plaintiff deadline on August 25, 2025 [1] Group 1: Class Action Details - Investors who purchased Sarepta securities between June 22, 2023, and June 24, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by August 25, 2025 [3] - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6] Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting their own achievements in this area [4] - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4] - Rosen Law Firm has been recognized for its performance in securities class action settlements, being ranked No. 1 in 2017 and consistently in the top 4 since 2013 [4] Group 3: Case Specifics - The lawsuit alleges that Sarepta made false and misleading statements regarding the safety and efficacy of its gene therapy, ELEVIDYS, which is intended for treating Duchenne muscular dystrophy [5] - Key issues raised include significant safety risks associated with ELEVIDYS, failure to detect severe side effects in trials, and the potential for regulatory scrutiny due to adverse events [5] - The lawsuit claims that these misrepresentations led to investor damages when the true information became public [5]

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Sarepta Therapeutics, Inc. regarding a class action lawsuit related to misleading statements about the safety and efficacy of its gene therapy product, ELEVIDYS [1][3]. Summary by Relevant Sections Allegations - The complaint alleges that during the class period from June 22, 2023, to June 24, 2025, Sarepta Therapeutics made materially false and misleading statements regarding ELEVIDYS, a gene therapy for Duchenne muscular dystrophy. Specific allegations include: - Significant safety risks associated with ELEVIDYS were not disclosed [3]. - Trial protocols failed to identify severe side effects [3]. - Adverse events from ELEVIDYS treatment could lead to halting recruitment and dosing in trials, attracting regulatory scrutiny [3]. - The misleading statements resulted in a lack of reasonable basis for the company's positive outlook on the therapy [3]. Class Action Details - Shareholders who purchased shares of SRPT during the specified class period are encouraged to register for the class action. The deadline for seeking lead plaintiff status is August 25, 2025 [4]. - Participants will be enrolled in a portfolio monitoring system to receive updates on the case [4]. Law Firm Background - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud. The firm aims to ensure companies engage in responsible business practices [5].

Core Viewpoint - The article discusses a class action lawsuit against Sarepta Therapeutics, alleging violations of the Securities Exchange Act of 1934 due to misleading statements regarding the safety and efficacy of its gene therapy product, ELEVIDYS, during a specified class period [1][3]. Company Overview - Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on developing therapies for Duchenne muscular dystrophy, including the gene therapy ELEVIDYS [2]. Allegations of the Lawsuit - The lawsuit claims that Sarepta and its executives made false or misleading statements about ELEVIDYS, including significant safety risks, failure to detect severe side effects, and the potential for halting clinical trials due to adverse events [3]. - Specific incidents cited include: - On March 18, 2025, a patient treated with ELEVIDYS suffered acute liver failure leading to death, causing Sarepta's stock to drop over 27% [4]. - On April 4, 2025, Sarepta disclosed that EU authorities requested a review of the death, leading to a further stock decline of over 7% [5]. - On June 15, 2025, a second patient died from acute liver failure, prompting Sarepta to suspend shipments and pause dosing, resulting in a stock drop of over 42% [6]. - On June 24, 2025, the FDA announced an investigation into the risk of acute liver failure associated with ELEVIDYS, causing an additional stock decline of over 8% [7]. Legal Process - The Private Securities Litigation Reform Act of 1995 allows investors who purchased Sarepta securities during the class period to seek appointment as lead plaintiff in the lawsuit, representing the interests of all class members [8].

RADNOR, Pa., July 8, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Sarepta Therapeutics, Inc. ("Sarepta") (NASDAQ: SRPT) on behalf of those who purchased or otherwise acquired Sarepta securities between June 22, 2023, and June 24, 2025, inclusive (the "Class Period"). The lead plaintiff deadline is August 25, 2025.CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP:If you suffered Sarepta losses, ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Sarepta To Contact Him Directly To Discuss Their OptionsIf you suffered losses exceeding $100,000 in Sarepta between June 22, 2023 and June 24, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, July 8, 2025 /PRNewswire/ -- ...

NEW YORK, July 8, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Sarepta Therapeutics, Inc. ("Sarepta" or the "Company") (NASDAQ: SRPT) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Sarepta investors who were adversely affected by alleged securities fraud between June 22, 2023 and June 24, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/sarepta-lawsuit-submission-f ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Sarepta Therapeutics, Inc. during the specified Class Period of the upcoming lead plaintiff deadline on August 25, 2025 [1]. Group 1: Class Action Details - Investors who purchased Sarepta securities between June 22, 2023, and June 24, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by August 25, 2025 [3]. - The lawsuit alleges that Sarepta made false and misleading statements regarding the safety and efficacy of its gene therapy product, ELEVIDYS, which is intended for treating Duchenne muscular dystrophy [5]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may not have the necessary experience or resources [4]. - The Rosen Law Firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company at the time, and has recovered hundreds of millions of dollars for investors [4]. Group 3: Case Specifics - The lawsuit claims that Sarepta failed to disclose significant safety risks associated with ELEVIDYS, which led to adverse events that could impact the therapy's approval and recruitment in clinical trials [5].

SAN DIEGO, July 07, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Sarepta Therapeutics, Inc. (NASDAQ: SRPT) securities between June 22, 2023 and June 24, 2025. Sarepta is a commercial-stage biopharmaceutical company that focuses on RNA and gene therapies for the treatment of rare diseases. During the class period, Sarepta was engaged in the development of therapies to treat Duchenne muscular dystrophy (“Duch ...